SCHEMBL6337233

SCHEMBL6337233

CC(=O)c1ccc(Oc2ccc(OCc3ccccc3)cc2C)nc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 7/20 0.55
ALDH1A1 P00352 1/20 0.48
HTT P42858 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
PPARG P37231 1/20 0.47
PPARD Q03181 1/20 0.47
GRM2 Q14416 1/20 0.46
CYSLTR1 Q9Y271 1/20 0.46
ACACB O00763 3/20 0.45
ACACA Q13085 3/20 0.45
FFAR1 O14842 1/20 0.45
NR4A1 P22736 1/20 0.45
NR4A2 P43354 1/20 0.45
NR4A3 Q92570 1/20 0.45
P4HTM Q9NXG6 1/20 0.44
CASP3 P42574 1/20 0.44
SENP8 Q96LD8 1/20 0.44
SENP7 Q9BQF6 1/20 0.44
SENP6 Q9GZR1 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6337213 0.92 NR4A2 (0.52) MAOBPPARGPPARDGRM2CYSLTR1
SCHEMBL6416751 0.91 MAOB (0.52) MAOBALDH1A1HTTSMN1; SMN2L3MBTL1
SCHEMBL6341086 0.89 MEN1 (0.47) MAOBSMN1; SMN2L3MBTL1PPARGPPARD
SCHEMBL6348703 0.86 PPARG (0.42) MAOBPPARGPPARDFFAR1NR4A1
SCHEMBL6347635 0.85 MAOB (0.59) MAOBALDH1A1HTTSMN1; SMN2L3MBTL1
SCHEMBL6346472 0.85 MAOB (0.69) MAOBALDH1A1HTTSMN1; SMN2L3MBTL1
SCHEMBL6349045 0.84 PPARD (0.49) MAOBPPARGPPARDACACBACACA
SCHEMBL6348828 0.83 GRM2 (0.54) GRM2CYSLTR1FFAR1NR4A1NR4A2
SCHEMBL6341725 0.81 OPRM1 (0.47) L3MBTL1GRM2CYSLTR1ACACBACACA
SCHEMBL1091737 0.79 MAOB (0.62) MAOBALDH1A1HTTSMN1; SMN2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6890932-B2 Immunoglobulin e antibody suppressors TEIJIN LIMITED (JP) 2005-05-10 US disclosed
EP-1101755-B1 ANTHRANILIC ACID DERIVATIVES TEIJIN LTD (JP) 2004-10-06 EP disclosed
US-20030232811-A1 Immunoglobulin e antibody suppressors TEIJIN LIMITED 2003-12-18 US disclosed
US-6649656-B1 Anticarcinogenic, antiallergen, antishock, and antiasthmatic agents TEIJIN LIMITED (JP) 2003-11-18 US disclosed
EP-1101755-A1 ANTHRANILIC ACID DERIVATIVES TEIJIN LIMITED (JP) 2001-05-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030232811-A1 Immunoglobulin e antibody suppressors IGLV6-57, FCGRT, IGSF11 MAOB 2681/4885ALDH1A1 250/4885HTT 4278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.